A great appetite to expand

The new plant in Binh Dinh province’s Quy Nhon city, with investment cost totalling €20 million, which took two years to build, will help Fresenius Kabi almost double its manufacturing capacity for infusion solutions and liquid medications.

Ulf Mark Schneider, CEO of Fresenius - the mother company of Fresenius Kabi, said: “Over the past decade, Vietnam’s economic growth has been amongst the highest in the world, achieving average annual growth rate of 7 per cent while per capita gross domestic product has trippled over the past 15 years.  And even though the growth rate has come down slightly in the wake of the global financial and economic crisis, Vietnam’s economy successfully continues on its growth path.”

He said: “Vietnam is one of Fresenius’ key growth markets and will continue to play a significant role in our Asia-Pacific strategy. As a result of the country’s strong growth and overall momentum, it is logical to build our own presence here in Vietnam.”

Jan Walter, managing director of Fresenius Kabi for Vietnam, Cambodia and Laos, told VIR that over the last three years, the company’s sales in Vietnam had grown by more than 20 per cent, per year.  “The new plant in Quy Nhon will significantly increase our production capacity and has the country’s most advanced production equipment for infusion solutions and liquid medications. So we are well equipped for the further growth that we expect to see at Fresenius Kabi in Vietnam over the next few years,” Walter said.

The new facility, to be run by Fresenius Kabi Bidiphar Joint Stock Company - a joint venture founded three years ago between Fresenius Kabi and local firm Bidiphar, covers 15,000 square metres. Its manufacture of infusion solutions is already certified in line with good manufacturing practice guidelines as set down by the World Health Organization.